ImmunityBio, Inc. (IBRX) income statement
IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.57−0.13 (-1.94%)
Close on Nov 19, 2026Market cap $6.96BP/E –Yield –
ImmunityBio, Inc. financial ratios
See a number that looks wrong?